IDO1 and melanoma: A phase III trial assessing the efficacy of IDO inhibition in combination with pembrolizumab in melanoma was not successful, highlighting the need to better understand metabolic checkpoint driven immune suppression and the role of other such checkpoints in immunotherapy responsive tumors like lung and melanoma.